Indian drug makers may lose out on outsourcing contracts as overseas pharmaceutical companies defer their visits to the country in the wake of Mumbai terror attacks, according to industry experts.
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
Saudi Arabia is insisting on 'In Kingdom' total value-addition requirements
The impact from NELM on the Indian pharmaceutical sector is estimated to be around Rs 6,000 crore.
Lupin will fund the buy through $100 mn cash reserves and a bridge loan.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances